Introduction
The uptake and retemion of oestrogen in high concentratin by breast cancer tissue may be related to the tumour's hormone dependence (Folca et al., 1961; Jensen et al., 1967; Jensen et al., 1971; Hahnel et al., 1971; Braunsberg et al, 1973) . The presence of active tissue oestrogen receptors in experimental and human mammary tumours can be shown by invivo and in-vitro itechniques using isotope-labelled oestradiol (Jensen et al., 1967; Johansson et al., 1970; Feherty et al.., 1971; Wittliff et al., 1971; Steggles and King, 1972; Terenius, 1972) . Such in-vitro studies may ultimately prove of value in discovering oestrogen dependence in women with advanced breast cancer and in predicting the likelihood of a response to antioestrogenic agents or to endocrine ablation procedures aimed at inhibifting endogenous oestrogen.
The stong affinity for labelled oestradiol of certain target organs and their itumours, both experimental and human, can be effectively blocked by synthetic non-steroidal compounds such as nafoxidine (U-l1, IOOA), ethamoxytriphetol, and clomiphene (Jensen et al., 1967; Sander, 1969; Terenius, 1971; Jensen et al., 1971) . The ability of such agents to interfere with oestradiol binding in target tissues may be explained by the competitive uptake of these compounds by cytoplasmic oestrogen receptors. By causing oestrogen deprivation of tumour tissue antioestrogens may prove of value as therapeutic agents for advanced breast cancer. They may also serve as indicators of tumour hormone dependence, and in such cases further endocrine therapy, including ablation procedures, may be worthwhile when the initial response to antioestrogen is no longer sustained.
In 1967 we reported the marked in-vivo inhibitory effect of an oestrogen antagonist, nafoxidine (U-li, IOOA), on the transplanted oestrogen-induced renal tumour of the Syrian hamster (Bloom et al., 1967) . In this model the effect of nafoxidine (1 mg subcutaneously daily) was abolished by the simultaneous administration of oestradiol (0-2 mg subcutaneously daily). After these laboratory experiments we suggested that nafoxidine might be of value in the treatment of patients with advanced cancer arising in the breast, endometrium, and possibly the kidney (Bloom et al., 1967 (Jensen et al., 1967; Terenius, 1971 patients: the four patients who died before four weeks of treatment were completed have been excluded from our figures. Complete or partial regression was observed in 11 of the 26 patients with locally advanced tumours involving the chest wall or nodes, and of the 14 of these patients who had tumours confined to the chest wall or nodes six responded. Only two of the 24 patients with skeletal metastases showed radiological signs of recalcification though pain was relieved in a further six such cases. A partial response of pulmonary metastases was seen in four out of seven cases and of hepatic metastases in two of six cases.
The dura,tion of the response to nafoxidine ranged from two to 36 months with a mean value of 11 months and a median value of nine months. Of the 18 women in whom objective regression occurred the response was maintained for six months in 17 and for one to three years in eight. Five patients showing a total or partial response are still under treatment (table I) . Compared with the resistant cases a greater proportion of patients who improved with nafoxidine had responded previously to other hormonal treatment. (Bloom et al., 1967) . Mr. J. M. Mallett examined these animals ophthalmoscopically after six and again af-ter 11 weeks of continuous treaftment with nafoxidine but found no lens changes. The hamsters, however, were caged in the normal animal rooms and not exposed to direct sunlight. Lens changes induced by nafoxidine may be part of a more general photosensitiza-tion effect rather -than a direct druginduced change (Cobb, 1972 (Turner et al., 1971 .
Despite the administration of nafoxidine evidence of oestrogen activity was seen in the vaginal smears in all the six cases examined. Interestingly this was so even when the pretreatment smear showed no or low oestrogen activity. A similar observation was made by the E.O.R.T.C. group (1972 (Jensen et al., 1971; Braunsberg et al., 1973) . This may be explained by the presence of a mixed population of tumour cells, with or without oestrogen receptors, and by different areas in the same tumour showing either high or low oestrogen-binding capacity (Hahnel et al., 1971) . We need to determine whether the inclusion of an antioestrogen such as nafoxidine in the in vitro test system based on tumour uptake of labelled oestradiol (Terenius, 1971 ) can achieve greater accuracy in predicting hormone responsiveness and in selecting patients for treatment.
It seems that in about one in three cases of advanced breast cancer i.n postmenopausal women an appreciable number of oestrogen-binding receptors are present and that most of these tumours will respond to antioestrogens or endocrine ablative procedures (Terenius, 1971; Jensen et al., 1971; Maass et al., 1972) . During our study the E.O.R.T.C. Breast Cancer Group reported objective remissions in 8 out of 25 (32%) cases of advanced breast cancer trea-ted for aft least two weeks with nafoxidine in a co-operative study at four centres (E.O.R.T.C., 1972). These results agree closely with our finding that 18 out of 48 (37%) cases treated with nafoxidine for at least a month showed an objective response.
Tamoxifen, another antioestrogen used recently in the treatment of advanced breast cancer, is the ,transisomer of 1 (p-8-dimethylaminoethoxy phenyl)-1, 2-diphenylbut-lene, which is also chemically related -to clomiphene. Cole et al. (1971) Feherty et al. (1971) . Ward's (1973) criteria of objective change,however, were less critical than ours, and he included some cases showing only "arrested" disease and 26 patients in whom the reduction in tumour size ranged between "50% and zero."
The continued search for antioestrogens as antifertility agents will no doubt lead to the discovery of more potent and perhaps more useful agents against oestrogen dependent tumours. In-vitro and in-vivo laboratory models using oestrogen dependent -tumours or normal target tissues may prove useful for screening potentially effective agents before human trial (Bloom et al., 1967) .
Conclusions Nafoxidine (U-li, 100A) and other antioestrogens may come -to play an important role in the treatment of women with advanced breast cancer which is no longer amenable to local measures and which also may have become resistant to previous endocrine treatment. The antioestrogens may prove more effective in the primary endocrine management of this disease than standard hormonal agents (oestrogens, androgens, and corticosteroids). Furthermore, nafoxidine is apparently devoid of serious side effeots on the cardiovascular system and gastrointestinal -tract and does not cause masculinization. Cutaneous dryness and photosensitivity are common but not serious complications. These, together with the possible small risk of cataract, can probably be avoided by protection from solar radiation or reduction in the dose of nafoxidine.
